Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKODYL vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. Metabolized to 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to plasma albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3–0.7 L/kg; clinical meaning: distributes into total body water, with higher Vd in neonates and patients with hepatic cirrhosis.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral (immediate-release): 80–100%; oral (sustained-release): 80–100% (subject to first-pass metabolism); rectal: approximately 80%.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
For GFR <30 m L/min: reduce dose by 50% and monitor serum levels; for GFR 30-60 m L/min: reduce dose by 25%.
No data; not applicable.
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75% or use alternative agent.
No data; not applicable.
Loading dose: 5-7 mg/kg IV over 30 minutes; maintenance: 0.5-1 mg/kg/hour IV continuous infusion or 10-20 mg/kg/day orally divided every 8-12 hours; adjust to achieve serum levels 5-10 mcg/m L.
No data; not applicable.
Start at lower end of dosing range (300 mg/day) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No data; not applicable.
No FDA black box warning.
None
Risk of toxicity due to narrow therapeutic index; monitor serum theophylline levels. Use caution in patients with peptic ulcer, seizure disorders, cardiac arrhythmias, or hepatic impairment. Smoking and certain drugs alter metabolism.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (unless on monitoring); uncontrolled seizure disorders; active peptic ulcer disease.
Hypersensitivity to arformoterol or any component of the formulation
High-fat meals may delay absorption; take consistently with food to avoid fluctuations. Charcoal-grilled foods and a high-protein, low-carbohydrate diet can increase metabolism of theophylline, reducing efficacy. Avoid concurrent use with caffeine-containing foods/beverages due to additive CNS stimulation.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Possible fetal tachycardia and jitteriness with maternal high doses; risk of neonatal withdrawal if used near term.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with milk-to-plasma ratio approximately 0.60-0.70. Concentrations in milk are about 2/3 of maternal serum levels. Irritability and sleep disturbance reported in nursing infants; monitor infant for signs of caffeine-like effects.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy may increase elimination of theophylline, especially in the third trimester, requiring dose adjustment. Monitor levels; may need 20-30% higher dose in third trimester. Postpartum, clearance decreases rapidly; reduce dose to prepregnancy levels.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
BRONKODYL (theophylline) has a narrow therapeutic index; serum levels should be monitored (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer, seizure disorders, or uncontrolled arrhythmias. Cimetidine, ciprofloxacin, and macrolides increase theophylline levels; smoking and rifampin decrease them. Use with caution in heart failure, hepatic impairment, and in elderly patients, as clearance is reduced.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take this medication exactly as prescribed; do not double doses if missed.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tremors, palpitations, or seizures.,Do not change brands or formulations without consulting your doctor, as bioavailability may differ.,Regular blood tests are necessary to monitor theophylline levels.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKODYL vs AEROLONE, answered by our medical review team.
BRONKODYL is a Bronchodilator that works by Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKODYL and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKODYL is: Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/m L.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKODYL and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKODYL is classified as Category C. BRONKODYL (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; animal studies show no consistent teratogenicity. Second and third trimesters: Po. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.